Pancreas cancer is characterized by a rapid and fatal outcome. It is a non-communicable disease showing increasing incidence mainly in Europe, North America and Japan. In the Czech Republic, the incidence of pancreas cancer has more than tripled over the last 50 years. The pancreas cancer incidence and mortality rates are practically identical in this country. The standardized incidence rates (world standard) are 10.4 in men and 7.1 in women, with the Czech Republic ranking the sixth and fourth in the world, respectively. The standardized mortality rates are 10.4 and 7.2, respectively, with the Czech Republic ranking the fourth and sixth to seventh in the world, respectively. Very rapid fatality is also indicative of the seriousness of the disease whose median survival ranges from three to six months.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pan-cancer secreted proteome and skeletal muscle regulation: insight from a proteogenomic data-driven knowledge base.
Funct Integr Genomics
January 2025
Department of Exercise Science and Health Promotion, Florida Atlantic University, Boca Raton, FL, USA.
Large-scale, pan-cancer analysis is enabled by data driven knowledge bases that link tumor molecular profiles with phenotypes. A debilitating cancer-related phenotype is skeletal muscle loss, or cachexia, which occurs partly from tumor products secreted into circulation. Using the LinkedOmicsKB knowledge base assembled from the Clinical Proteomics Tumor Analysis Consortium proteogenomic analysis, along with catalogs of human secretome proteins, ligand-receptor pairs and molecular signatures, we sought to identify candidate pan-cancer proteins secreted to blood that could regulate skeletal muscle phenotypes in multiple solid cancers.
View Article and Find Full Text PDFPrognostic factors of the survival of pancreatic cancer patients in peninsular Malaysia: A survival analysis.
Med J Malaysia
January 2025
Universiti Sultan Zainal Abidin, Faculty of Medicine, Kampus Perubatan, Jalan Sultan Mahmud, Kuala Terengganu, Malaysia.
Introduction: Pancreatic cancer incidence in Malaysia is steadily on the rise, now ranking as the 14th most common malignancy in the country. Despite this upward trend, research on prognostic factors affecting pancreatic cancer survival remains limited, highlighting the need for ongoing investigation to improve patient survival outcomes.
Materials And Methods: This study was conducted retrospectively by reviewing records of pancreatic cancer patients hospitalized between January 2011 and December 2018 across multiple health centres in Malaysia.
Comparative Analysis of Long-Standing and Newly Diagnosed Diabetes Mellitus in Patients with Pancreatic Ductal Adenocarcinoma: A Tunisian Multicenter Study.
Tunis Med
January 2025
University of Sousse, Faculty of Medicine of Sousse, 4002, Farhat Hached University Hospital, Department of Endocrinology Diabetology, 4000, Sousse, Tunisia.
Introduction: Diabetes mellitus has emerged as a global public health issue due to its increasing prevalence and the increased risk of developing cancers. Pancreatic cancer is believed to be both a consequence of pre-existing diabetes and a potential cause of new-onset diabetes.
Aim: This study aims to compare the characteristics of patients with pancreatic ductal adenocarcinoma and newly diagnosed or long-standing diabetes mellitus.
Improved Predictability of Diagnosis and Prognosis Using Serum- and Tissue-Derived Extracellular Vesicles From Bulk mRNA Sequencing in Pancreatic Ductal Adenocarcinoma.
Cancer Med
January 2025
Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.
Background: Early-stage pancreatic ductal adenocarcinoma (PDAC) is frequently misdiagnosed, contributing to its high mortality rate. Exosomal microRNAs (miRNAs) have emerged as potential biomarkers for the early detection of PDAC.
Aims: This study aimed to evaluate the feasibility of using exosomal miRNAs from PDAC tissues and serum as biomarkers for early detection and prognosis.
An OMV-Based Nanovaccine as Antigen Presentation Signal Enhancer for Cancer Immunotherapy.
Adv Mater
January 2025
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, 210029, China.
Antigen-presenting cells (APCs) process tumor vaccines and present tumor antigens as the first signals to T cells to activate anti-tumor immunity, which process requires the assistance of co-stimulatory second signals on APCs. The immune checkpoint programmed death ligand 1 (PD-L1) not only mediates the immune escape of tumor cells but also acts as a co-inhibitory second signal on APCs. The serious dysfunction of second signals due to the high expression of PD-L1 on APCs in the tumor body results in the inefficiency of tumor vaccines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!